The problem of the treatment of carotid stenosis in patients with contralateral carotid occlusion has not yet been resolved. The data in the literature are not clear in this regard and there is no unanimous agreement on the best technique to be used, specifically stenting or endarterectomy. Therefore, we have reviewed our own results on an extensive number of patients and analyzed the available literature using a meta-analysis.
INTRODUCTION
Carotid artery stenosis is associated with contralateral carotid artery occlusion (CCO) in approximately 10% of patients. 1e3 In those patients, cerebral perfusion is maintained by the contralateral stenosed carotid artery and by the vertebro-basilar circulation, through the circle of Willis. The revascularization procedures available for carotid stenosisdendarterectomy (CEA) and stenting (CAS)din patients with CCO can temporarily decrease cerebral flow and could influence the outcome of the procedure. 4e6 Several series of CEA include CCO as a predictor of perioperative neurologic events, 7e10 although some others do not. 11e14 In CAS, CCO does not appear to influence the outcome. 15, 16 Few papers are available in the literature that directly compare the results of CEA and CAS in patients with CCO.
The aim of the present work was to evaluate the influence of CCO on the perioperative outcome in a series of patients submitted to CEA and CAS, and to analyze the experience reported in the literature through a metaanalysis.
METHODS

Study design and setting
Consecutive patients who were submitted to carotid revascularization from January 2005 to December 2011 in a single centre were prospectively entered into a dedicated database and retrospectively reviewed. All patients gave their informed consent for the procedure.
The main aim of the study was to evaluate and compare the influence of CCO on the primary outcome (any postoperative cerebral event and death) in CEA and CAS. We also evaluated the influence of the preoperative symptoms on the results of CEA and CAS in patients with and without CCO.
Variables and surgical methods
Carotid revascularizations were performed according to the European Society of Vascular and Endovascular Surgery guidelines. 17 The clinical characteristics, technical aspects, preoperative neurologic symptoms, and perioperative (30-day) outcome were considered. The clinical characteristics specifically included the following: age; sex; hypertension (presence of a systolic blood pressure of >140 mmHg and/ or a diastolic blood pressure of >90 mmHg, or specific therapy); dyslipidemia (total cholesterol >200 mg/dL or low density lipoprotein >120 mg/dL, or specific therapy); diabetes mellitus (prediagnosed in therapy with oral hypoglycemic drugs or with insulin); current smoking; coronary artery disease (CAD, defined as a history of angina pectoris, myocardial infarction, or coronary revascularization); chronic obstructive pulmonary disease (defined as chronic bronchitis or emphysema); and chronic renal failure (CRF, a glomerular filtration rate of <60 mL/min). The preoperative neurologic symptoms were evaluated by independent inhospital neurologists and were defined as transient ischemic events or strokes occurring in the last 24 weeks in the hemisphere ipsilateral to the target carotid stenosis.
Carotid revascularization was performed for symptomatic carotid artery bifurcation stenosis of >60% (according to the North American Symptomatic Carotid Endarterectomy Trial [NASCET] criteria 18 ) and asymptomatic carotid artery stenosis of >70% (according to the NASCET criteria), as suggested by the European Society of Vascular and Endovascular Surgery guidelines. 17 The CEA procedures were performed with routine shunting and patching.
In patients with appropriate clinical or anatomic characteristics, the CAS procedure was performed as described previously. 19 Briefly, the patients were taken to the angiographic suite after providing appropriate informed consent. A cardiologic evaluation was performed, and the patients were medicated with 100 mg aspirin and 75 mg clopidogrel for 3 days before the procedure. All procedures were performed under local anesthesia and systemic heparinization, and with an 8F groin introducer. Common carotid cannulation was achieved using 40 Boston Scientific (Natick, MA, USA) or Medtronic (Minneapolis, MN, USA) HS I and II catheters over a Terumo (Leuven, Belgium) stiff guide wire. When cannulation could not be achieved by these means, several alternative techniques were used (i.e., buddy wire or coaxial). Brachial or carotid access was not attempted in any case. Routine cerebral protection was accomplished using FilterWire EZ (Boston Scientific) and closed-cell stenting (Wallstent, Boston Scientific) was used. "Technical success" was defined as treatment resulting in less than 30% residual stenosis. The neurologic outcomes were evaluated both at the end of the procedure and over the following 24 h by a neurologist using the National Institutes of Health stroke scale and the modified Rankin scale.
As perioperative (30-day) outcomes we considered cerebral events (considered to be postoperative stroke that was clinically evaluated by the neurologist and with a new acute ischemic lesion identified by a cerebral computed tomography scan, or a transient cerebral ischemic event and transient focal neurologic deficit with complete resolution within 24 h, and no new ischemic lesion on the cerebral computed tomography scan) and death. For a clear analysis of the results, the occurrence of any cerebral event or death was considered cumulatively to be a primary adverse outcome; secondary adverse outcomes were evaluated separately for each category of complications (transient cerebral events, stroke, and death).
Statistical methods
Continuous variables were expressed as mean AE SD and frequencies by percentages. Analyses of the differences between the two groups were performed using Fisher's exact test or chi-square test for categorical variables and unpaired Student t test, or the ManneWhitney U test for continuous variables. The multivariable analyses were performed using the regression model including the significant (p < .05) or closing significant (p < .20) variables from the previous univariable analysis in the models. A value of p < .05 (2-tailed) was considered to be significant. The statistical tests were performed using SPSS 13.0 for Windows (SPSS, Chicago, IL, USA).
Meta-analysis methods
Research protocol, eligibility criteria, and study selection. An English-language literature review was performed through PubMed, Scopus, and Science Direct for any study reporting the outcome in terms of stroke and death after carotid revascularization by CEA or CAS, including the results from patients with CCO, until March 2012.
Two investigators (RP and RM) performed the research. The mesh terminology used for search purposes included . The investigators independently reviewed the titles and abstracts of all citations to identify potentially relevant studies and to exclude duplicates. They reviewed the full text of the corresponding publications to assess if the studies met the inclusion criteria. The references from the articles obtained were also analyzed. The exclusion criteria were as follows: case reports; studies with no extractable data on stroke and death; and multiple publications on overlapping populations. Unpublished data or data reported only in abstracts were not included. The final inclusion of the studies was based on agreement between the reviewers. We resolved disagreements by discussion and consultation with the other authors if necessary. The articles were categorized to perform three meta-analyses: the first two analyses evaluated the influence of CCO on the postoperative stroke and death rates after the CEA and CAS procedures; the third aimed to analyze data from articles comparing CEA and CAS outcomes in patients with CCO. Prospective, retrospective, and case-control studies were included in the first two meta-analyses; the third meta-analysis include only randomized controlled trials. We applied the guidelines for the Meta-analysis of Observational Studies in Epidemiology. 20 Data extraction and quality assessment. Three investigators (RP, RM, and GF) used the standardized extraction database (Microsoft Excel) to extract information on outcome (number of patients and 30-day event rates for death and stroke) with odds ratios (ORs). We assessed study quality by evaluating the indication for the carotid revascularization procedures, the cerebral protection device used in CAS, the clinical evaluation of complications, and the follow-up.
Subgroup evaluations. A number of subgroups were also analyzed. Primarily, symptomatic and asymptomatic patients were compared. Next, to identify those studies with a higher statistical power, the sample size population was evaluated: considering the presence of CCO in 10% of patients submitted to carotid revascularization, an a error of 5% and a b error of 20%, the sample required identifying a difference in the outcome of 3% (from 2% to 5%) was approximately 300 and 2,800 in procedures with CCO and without CCO, respectively. 21 A further subgroup analysis was performed according to shunting during the CEA procedures: studies were stratified into "no shunt" if shunting was never used; "selective shunt" if shunting was performed depending on clinical, anatomical, or technical criteria (electroencephalogram [EEG] modification, clinical modification during loco-regional anesthesia, stump pressure evaluation, somatosensory-evoked potential, cerebral angiographic evaluation, transcranial Doppler sonography or near-infrared spectroscopy evaluation); and "routine shunting" if shunting was performed whenever technically possible.
Study bias evaluation. The bias evaluation (performed by RP) focused on the indication for carotid revascularization, the technical characteristics, the evaluation of the outcomes, and the follow-up. The inter-study bias evaluation was performed by funnel plot symmetry evaluation.
Statistical analysis was performed using RevMan 5.2 (Copenhagen, Denmark) and Meta-analyst 3.13 (Boston, MA, USA) software. The pooled stroke and death risk was expressed as an OR with a 95% confidence interval (CI). Heterogeneity among the studies was estimated by the chi-square test and Cochran Q score, reported as I 2 and representing the percent value of heterogeneity. Because of the heterogeneity of the observational studies, we assessed a priori by a random effect model. The test for overall effect was a Z test and the statistical significance level was set to p < .05. The data were graphed as a forest plot. In the multivariable analysis using the binary regression model, the CEA was independently associated with a lower incidence of the primary outcome (any cerebral event and death) with an OR of 0.35 and a 95% CI of 0.20e0.63. This analysis was based on the preoperative neurologic symptoms, sex, age > 80 years, CAD, CRF, dyslipidemia, and smoking.
RESULTS
CEA vs. CAS in the entire population
CEA outcomes in presence of CCO
During the study period, 706 CEA were performed, with 37 (5.2%) in CCO patients. The clinical and surgical technical characteristics were similar in the CCO and other patients submitted to CEA ( Table 1 ). The incidence of postoperative events was significantly higher in patients with CCO compared with patients without CCO: 5 (13.5%) vs. 19 (2.9%) primary adverse outcomes (any cerebral event and death), p ¼ .001. The CCO patients had a higher incidence of secondary adverse outcomes compared with the no-CCO patients: 2 (5.4%) vs. 6 (0.9%), p ¼ 0.01 transient cerebral events; 3 (8.1%) vs. 10 (1.7%), p ¼ .007 strokes; 5 (13.5%) vs. 16 (2.4), p ¼ .001 all cerebral events; and 1 (2.7%) vs. 3 (0.5%), p ¼ .07 deaths.
As shown in Table 2 , among the 189 symptomatic patients submitted to CEA, 13 (6.3%) had CCO. A significant difference was observed with respect to the primary adverse outcomes between the CCO and non-CCO patients: 3 (25%) vs. 7 (4%), p ¼ .02. No significant differences were observed with respect to the secondary adverse outcomes: strokes (there were no transient cerebral events in symptomatic patients) and death rate were 2 (15.2%) vs. 7 (4.0%), p ¼ .12 and 1 (7.7%) vs. 0 (0%), p ¼ .06, respectively. There were 517 asymptomatic patients submitted to CEA, with 15 (3.0%) having CCO. As shown in Table 2 , the asymptomatic patients with CCO had a higher primary adverse outcome rate compared with asymptomatic patients with no CCO (3 [ [2.5] , p ¼ .02, respectively). For the secondary adverse outcomes, no significant difference was observed between the CCO and non-CCO patients.
In the multivariable analysis using the binary regression model, the presence of CCO was independently associated with a higher overall complication rate (any cerebral event and death) with an OR of 5.1 and a 95% CI of 1.7e14.5. This analysis was based on the preoperative neurologic symptoms, sex, statin therapy, dyslipidemia, and age >80 years.
CAS outcomes in the presence of CCO
During the study period, 512 CASs were performed, with 38 (7.4%) in CCO patients. Clinical characteristics and endovascular technique were similar in patients with CCO and with no CCO (Table 1 ). The primary adverse outcome rate was not significantly different among the two groups: 1 (2.6%) in the CCO patients vs. 42 (8.8%) in the non-CCO patients, p ¼ .18. As shown in Table 1 , the secondary adverse outcome rate was not significantly different between the patients with CCO and with no CCO.
As shown in Table 2 , the primary adverse outcomes were not significantly different in the symptomatic patients with and without CCO: 0 (0%) vs. 16 (11.9%), p ¼ .61.
Similarly, the primary adverse outcomes were not significantly different in the asymptomatic patients with and without CCO: 1 (3.7%) vs. 26 (7.6%), p ¼ .70. .07 0 (0.0) 0 (0.0) 1.0 Note. Categorical variables are expressed as percentage and compared using the chi-square test; p < .05 was considered to be significant. a Continuous variables are expressed as means AE SD and compared using the Student t test; p < .05 was considered to be significant. In the multivariable analysis using the binary regression model the presence of CCO was not associated with a higher primary outcome incidence (any cerebral event and death): OR of 0.3 and 95% CI of 0.04e2.31; the analysis was based on preoperative neurologic symptoms, sex, and age >80 years.
CEA vs. CAS in CCO patients
CCO was present in 37 patients submitted to CEA and 38 patients submitted to CAS. The clinical characteristics were similar in both groups of patients except for the higher incidence of CAD and CRF, and the older age of patients submitted to CAS (Table 3 ).The primary adverse outcomes in the CEA and the CAS CCO patients were 6 (16.2%) and 1 (2.7%), p ¼ .04, respectively. No significant differences were found in the secondary adverse outcomes in these two groups (Table 3) . Fig. 1 shows the study selection process. We found 27 papers on CEA and 6 on CAS with data available for the metaanalysis of patients with CCO and non-CCO, and no papers with stroke and death data for patients with CCO submitted to CEA or CAS.
Meta-analysis results
CEA in patients with CCO. Twenty-seven studies met the inclusion criteria. Seventeen were retrospective singlecentre studies, 1,7,11e14,22e32 four were retrospective multicentre studies, 8e10,33 one was a case-control study, 34 one was a prospective single-centre study, 35 and four were randomized controlled trials. 2, 3, 36, 37 Fig. 2 shows the forest plot of all studies; the overall OR was 1.82 (95% CI: 1.57e 2.11), with a low level of heterogeneity (I 2 ¼ 0%) and a high level of significance (Z ¼ 7.83, p < .00001).
Two studies 1,3 met the inclusion criteria for the subgroup meta-analysis of CEA in symptomatic patients with CCO compared with no CCO. As shown in the forest plot in Fig. 3 , the CCO had an OR of 2.43 (95% CI: 1.07e5.50) and a moderate level of heterogeneity
Four studies met the inclusion criteria for the subgroup meta-analysis of CEA in asymptomatic patients with CCO compared with those without CCO, as shown in the forest plot in Fig. 3 , the CCO had an OR of 1.83 (95% CI: 1.25e 2.68) and a low level of heterogeneity
In the meta-analysis subgroup of studies with a higher statistical power, five studies met the inclusion criteria ( Fig. 3): 8e10,31,33 the OR was 1.75 (95% CI: 1.44e2.12), and there was a low level of heterogeneity
In the evaluation of shunt use during CEA 18 studies met the inclusion criteria. In two studies, the CEA was performed with no shunt use (Fig. 4) , 10, 24 but, in the study of Frawley et al., 24 thiopental sodium was used in cases of EEG modification. Both studies showed a trend of an increased risk of stroke and death in patients with CCO compared with patients with no CCO. This trend was confirmed by the metaanalysis: the OR was 2.61 (95% CI 0.91e7.46) and a low level of heterogeneity I 2 ¼ 7% (Z ¼ 1.79, p < .07) was found. The results of CEA performed with selective shunting were reported in 12 studies: three with EEG evaluation, 12, 25, 34 one with evaluation by preoperative cerebral angiogram, 35 one with stump pressure, 27 one with somatosensory-evoked potential, 28 two with a clinical evaluation during loco-regional anesthesia, 1, 26 and one with a decision made at the surgeon's discretion. 7 Three studies reported multiple types of evaluation: two used EEG or clinical evaluation during locoregional anesthesia, 30, 31 and one used EEG or clinical evaluation during loco-regional anesthesia or stump pressure evaluation. 10 The presence of CCO was also a risk factor for stroke and death in the meta-analysis of studies reporting the use of selective shunting with an OR of 1.83 (95% CI: 1.34e 2.52) and a low level of heterogeneity I 2 ¼ 0% (Z ¼ 3.77, p < .0002) (Fig. 4) . We considered the different methods for the evaluation of whether to use shunting to be a possible bias across the studies.
Six studies 10, 11, 13, 29, 32, 37 reported the results from CEA in CCO patients compared with no-CCO patients with routine shunt use; CCO was a risk factor of stroke and death in the studies reporting the use of routine shunting with an OR of 2.14 (95% CI: 1.28e3.32) and a low level of heterogeneity I 2 ¼ 0% (Z ¼ 3.40, p < .0007) (Fig. 4) . The inter-study bias evaluation of patients who have undergone CEA with and with CCO was performed by the funnel plot analysis, which showed a good level of symmetry.
CAS in patients with CCO. Six studies met the inclusion criteria. 15,16,38e41 All of these studies were retrospective studies, with one being a national (German) registry 38 and five being single-centre experiences. 15,16,31e41 All studies included symptomatic and asymptomatic patients, but did not divide the patients into those with or without CCO. No studies were appropriate for the subgroup meta-analysis (either for symptomatic status or the sample size). Fig. 5 shows the forest plot of all studies: the overall OR was 1.22 (95% CI: 0.60e2.49); there was a low level of heterogeneity: I 2 ¼ 23% (Z ¼ 0.55, p < .58). The inter-study bias evaluation of patients who underwent CAS with and with without CCO was performed by funnel plot (Fig. 6) analysis, which showed a low level of symmetry.
CEA vs. CAS in patients with CCO. The International Carotid Stenting Study (ICSS) 42 included the data and outcome of patients with CCO submitted to CEA and CAS, but presented this information as the composite outcome of stroke, death, and myocardial infarction. The ICSS included 49 patients with CCO in the CAS group and 37 in the CEA group, and all patients were symptomatic. There were two (4.3%) events in the CAS group with CCO and one (3.7%) in the CEA group with CCO, with no significant difference between the two groups (OR: 1.51, 95% CI: 0.14e16.61).
DISCUSSION
The present observational, nonrandomized study on 1,218 carotid revascularizations showed that CEA is generally associated with a minor perioperative incidence of any cerebral event and death compared with CAS (3.2% vs. 8.3%, p ¼ .001). These results are similar to those of the most recent, wider, randomized controlled trials (Carotid Revascularization Endarterectomy or Stent Trial (CREST) 43 and ICSS 42 ), which had stroke/death rates of 2.3% vs. 4.4% (p ¼ .005) and 4.2% vs. 8.0% (p ¼ .001), respectively.
CCO is an uncommon condition in patients submitted to contralateral carotid revascularization: 6.1% in our series, which is consistent with 5e10% reported in other studies. 1e3 In our series, CCO was an independent risk factor of adverse events (for any cerebral event and death) in CEA, with an OR of 5.1 (95% CI: 1.7e14.5), but not in CAS. The comparison of the two carotid revascularization techniques in patients with CCO showed a higher incidence of adverse events in patients submitted to CEA compared with those submitted to CAS (16.2% vs. 2.6%, p ¼ .04). The analysis of our own data, however, had several confounding elements owing to the observational nonrandomized design of the study. Patients submitted to CAS were more frequently older, with coronary artery disease and chronic renal failure. Despite these clinical differences CAS showed better results compared with CEA in CCO patients.
The influence of CCO in the CEA patients is reported differently in the literature. CCO is reported to be a risk factor for adverse CEA outcomes by subgroup analysis of different randomized controlled trials in both symptomatic 1, 3 and asymptomatic patients, 1, 2, 8, 36 with an increasing risk of postoperative cerebral events of up to 14%. NASCET showed that the 30-day risk of stroke/death was significantly higher in symptomatic patients with CCO (14.3%) compared with patients with a patent contralateral internal carotid artery (approximately 5%). Despite the higher operative risk, CEA still lead to a highly significant reduction of the 2-year risk of ipsilateral stroke compared with medically-treated patients (absolute risk reduction: 47.3%). In asymptomatic patients, the issue is more controversial. 3 In post hoc Asymptomatic Carotid Atherosclerosis Study data analysis Becker et al. 36 concluded that "endarterectomy in asymptomatic subjects with contralateral occlusion provides no long-term benefit (and may be harmful) in preventing stroke and death" because of the increased perioperative complications in the surgical arm. In contrast, many other authors do not consider CCO as being a significant risk factor for CEA. 11e14 In patients submitted to CAS, CCO is not considered to be a risk factor of adverse outcome by any researchers because these patients have similar results compared with patients with patency of contralateral internal carotid artery. 15,16,38e41 However, the definitive role of CAS remains controversial, particularly in asymptomatic patients. Even if most complications in our series were transient cerebral events with a prompt, uneventful recovery, the cumulative adverse event rate was 12% in symptomatic patients and 8% in asymptomatic patients, with postoperative stroke rates of 6.6% and 1.8%, respectively. Therefore, our data confirm the contemporary recommendations of the major vascular societies favoring CEA rather than CAS in asymptomatic patients 17 given the higher risk of the latter technique. However, because the presence of CCO appears to increase the risk of complications, particularly in the surgical arm, CCO itself can be added to other characteristics to be considered in the choice of the revascularization technique, similarly to other anatomical factors.
In the present series, the low number of carotid revascularization procedures in CCO patients, the retrospective design, and the statistical limitation did not allow a comparison of the surgical and endovascular techniques. However, our results suggest a better outcome of CAS compared with CEA in patients with CCO.
In general, randomized clinical trials comparing CEA with CAS do not specifically address the influence of CCO. The meta-analysis of different trials (ICSS, 42 CREST, 43 StentSupported Percutaneous Angioplasty of the Carotid Artery (SPACE) 44 and Endarterectomy vs Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA3S) 45 ) showed that the presence of CCO or contralateral severe carotid stenosis was associated with the same outcome of CEA. To better analyze the issue, we performed a meta-analysis of the papers reporting the results of CEA and CAS in patients with CCO. The outcome of the meta-analysis was in accordance with our own results: in the CEA group CCO is a risk factor for stroke and death in both symptomatic and asymptomatic patients. This finding holds true in the subgroup analysis, particularly in those papers with a higher statistical power (Fig. 3) .
Shunting, either routine or selective, did not influence the overall results. Independent from the use of a shunt during the CEA procedures, CCO remained a predictor of stroke and death in the meta-analysis. This result could be explained by greater atherosclerotic involvement of the cerebral vessels in patients with CCO. Two papers 10, 24 reporting the outcome of CEA performed routinely without shunting failed to show a difference between patients with and without CCO, but did show a trend with of CCO as a risk factor. The reasons for this association are difficult to explain. In one series, cerebral protection was obtained through high dosage of thiopental sodium in cases of EEG modification, which may partially explain the results. 24 Additionally, we can consider the different methods used to evaluate the indication for shunting (EEG, locoregional anesthesia, stump pressure, somatosensory evoked potential, cerebral angiography, transcranial Doppler sonography, or near-infrared spectroscopy) as a possible selective bias of the meta-analysis.
In patients submitted to CAS, CCO does not influence the outcome of the procedure (Fig. 5) . We only found one paper reporting a comparative analysis of CEA and CAS in patients with CCO. In that trial, which reported the results of 86 patients with CCO submitted to CEA (37 patients) or CAS (49 patients), both techniques led to a similar outcome. 42 Similarly, unpublished data from the Society for Vascular Surgery Vascular Registry, recently presented at the 2012 Society for Vascular Surgery meeting, confirm the present results, reporting a higher incidence of stroke, death, and myocardial In conclusion, CCO appears to be a risk factor in CEA, but not in CAS. The superiority of one revascularization technique over the other, however, must be demonstrated in this setting, and further studies comparing CAS and CEA in patients with CCO should therefore be performed. 
